Pertussis Market Expected to Experience Accelerated Growth and Market Evolution by 2036 - DelveInsight

DelveInsight's "Pertussis - Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Pertussis, historical and forecasted epidemiology, as well as the Pertussis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Get more details on the "Pertussis - Market Insights, Epidemiology and Market Forecast" Report:
https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Pertussis Market Report

• In February 2026, ILiAD Biotechnologies secured an oversubscribed USD 115 million Series B to advance BPZE1 pertussis vaccine development.
• According to DelveInsight's analysis, the Pertussis market size was found to be ~USD 4,000 million in the leading markets (the US, EU4, the UK, and Japan) in 2025, projected to reach USD 5,000 million by 2036 at a 2.7% CAGR (2026-2036).
• The total market size in the US for pertussis was estimated at nearly USD 3,200 million in 2025, expected to increase due to the launch of emerging therapies and label expansion of current therapies.
• The rising incidence of pertussis, due to inadequate immunization and waning immunity among vaccinated groups, is driving market demand for vaccines and treatments.
• Currently, the vaccines available in the 7MM include ADACEL, BOOSTRIX, HEXAXIM, VAXELIS, QUADRACEL, TETRABIK, TRIBIK/BK1301, and others.
• BPZE1, ILiAD Biotechnologies' novel intranasal, live attenuated pertussis vaccine candidate, received US FDA Fast Track status in January 2022 for pertussis booster immunization; Phase IIb data demonstrated strong safety, induction of mucosal immunity, and up to 90% prevention of bacterial colonization upon challenge.
• DPT-IPV-Hib (BK-1310/MT-2355), co-developed by Mitsubishi Tanabe Pharma Corporation with the Research Foundation for Microbial Diseases of Osaka University, has completed Phase III trials; in April 2022, an application for marketing authorization was submitted to Japan's Ministry of Health, Labour and Welfare.
• In 2025, the US accounted for the highest cases of pertussis, i.e., 60% of the total cases in the 7MM; the total Pertussis vaccinated population in the US was approximately 20 million in 2025, projected to increase during the forecast period (2026-2036).
• In the 7MM, PENTACEL leads in market size due to high-volume pediatric use, while BOOSTRIX shows strong growth potential driven by expanding booster and maternal immunization programs; the market share of Spain for pertussis was found to be the lowest in 2025.
• Key Pertussis Companies: Sanofi, GSK, Biken, KM Biologics, ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, Cansino Bio, and others.
• Key Pertussis Therapies: DAPTACEL, INFANRIX, PEDIARIX, KINRIX/INFANRIX VPI, PENTACEL, HEXAXIM/HEXYON/HEXACIMA, BOOSTRIX/BOOSTRIX TETRA, TETRABIK, TRIBIK/BK1301, QUATTROVAC, REPEVAX (ADACEL QUADRA; ADACEL-POLIO), TETRAVAC/TETRAXIM, INFANRIX HEXA, BPZE1, DPT-IPV-HiB (BK-1310/MT-2355), DTcP, and others.

Pertussis Overview

Pertussis, literally meaning "a violent cough" and commonly known as whooping cough or the "cough of 100 days," is an acute, highly contagious respiratory infection caused by Bordetella pertussis. First recognized during the Paris epidemic of 1578, the disease is characterized by a prolonged paroxysmal cough lasting ≥2 weeks, often accompanied by an inspiratory "whoop," posttussive vomiting, and syncope. Although traditionally considered a childhood disease, over half of reported cases now occur in adolescents and adults, largely due to waning immunity (declining to ~50% within 12 years post-vaccination). Transmission occurs via respiratory droplets, and the disease progresses through three stages: catarrhal, paroxysmal, and convalescence.

To know in detail about the Pertussis market outlook, drug uptake, treatment scenario, and epidemiology trends, refer to the full report:
https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Pertussis Epidemiology

The epidemiology section provides insights segmented by total Pertussis vaccination coverage across the geographies covered: North America (the US); Europe (Germany, France, Italy, Spain, and the UK); and Asia-Pacific (Japan).

Key Findings from Pertussis Epidemiological Analysis and Forecast

• In 2025, the US accounted for the highest cases of pertussis, i.e., 60% of the total cases in the 7MM.
• Among the 7MM, vaccination coverage for children is reported to be high, while booster vaccination compliance among adults is reported to be low; increasing awareness, updated immunization recommendations, and the entry of emerging vaccines are expected to increase the vaccination coverage rate.
• As per DelveInsight's estimate, the total Pertussis vaccinated population in the US was approximately 20 million in 2025, projected to increase during the forecast period (2026-2036).
• Pertussis infection can lead to complications, particularly pneumonia in infants and older adults; in severe cases, infants may show signs such as poor feeding, irritability, and unusual tiredness, with breathing difficulties potentially progressing to respiratory distress.

Pertussis Epidemiology Segmentation

• Total Pertussis Vaccination Coverage

Pertussis Drugs Uptake and Pipeline Development Activities

The drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials, covering mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with advantages, limitations, and recent developments.
Established booster vaccines such as ADACEL/REPEVAX and BOOSTRIX demonstrate strong and sustained uptake, supported by proven safety, immunogenicity, and increasing adoption in maternal immunization. Combination pediatric vaccines such as HEXAXIM/HEXYON/HEXACIMA and VAXELIS are expected to show progressive and widespread uptake, driven by their ability to simplify immunization schedules and improve compliance in infants.

Pertussis Therapies and Key Companies

• ADACEL/REPEVAX: Sanofi (Sanofi Pasteur)
• BOOSTRIX: GlaxoSmithKline
• HEXAXIM/HEXYON/HEXACIMA: Sanofi
• VAXELIS: Merck and Sanofi
• BPZE1: ILiAD Biotechnologies
• DPT-IPV-Hib (BK-1310/MT-2355): Mitsubishi Tanabe Pharma Corporation
• DTcP: Cansino Bio

Discover more about therapies set to shape the Pertussis market landscape:
https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Pertussis Market Drivers

• Increasing disease awareness and surveillance, with improved diagnosis and reporting systems leading to higher detection and recognition of pertussis cases globally.
• Waning immunity and the need for booster vaccinations, driving demand for Tdap booster vaccines in adolescents, adults, and pregnant women.
• Expansion of immunization programs, supported by strong government initiatives and inclusion of combination vaccines in national schedules, boosting vaccination coverage and market growth.

Pertussis Market Barriers

• Intense competition in the pertussis vaccine market, with multiple key players vying for market share, may lead to price wars that reduce profitability and discourage investment in new and improved vaccines, potentially hindering innovation and long-term market growth.
• The accurate and timely diagnosis of pertussis continues to be challenging, with culture-based isolation of B. pertussis considered insensitive despite being the traditional gold standard; unmet needs include the resurgence of pertussis, vaccine failure, remaining gaps in disease control, and a lack of proper epidemiology data.

Scope of the Pertussis Market Report

• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: Global
• Key Pertussis Companies: Sanofi, GSK, Biken, KM Biologics, ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, Cansino Bio, and others
• Key Pertussis Therapies: DAPTACEL, INFANRIX, PEDIARIX, KINRIX/INFANRIX VPI, PENTACEL, HEXAXIM/HEXYON/HEXACIMA, BOOSTRIX/BOOSTRIX TETRA, TETRABIK, TRIBIK/BK1301, QUATTROVAC, REPEVAX, TETRAVAC/TETRAXIM, INFANRIX HEXA, BPZE1, DPT-IPV-HiB (BK-1310/MT-2355), DTcP, and others
• Pertussis Therapeutic Assessment: current marketed and emerging therapies
• Pertussis Market Dynamics: market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis
• Pertussis Unmet Needs, KOL Views, Market Access and Reimbursement

Table of Contents

• Pertussis Market Key Insights
• Pertussis Market Report Introduction
• Pertussis Market Executive Summary
• Pertussis Market Key Events
• Pertussis Market Forecast Methodology
• Pertussis Market Overview
• Pertussis Market Disease Background and Overview
• Pertussis Market Treatment Guidelines
• Pertussis Market Epidemiology and Patient Population
• Pertussis Market Patient Journey
• Pertussis Marketed Therapies
• Pertussis Emerging Drugs
• Pertussis Market Analysis
• Pertussis Market Unmet Needs
• Pertussis Market SWOT Analysis
• Pertussis Market KOL Views
• Pertussis Market Access and Reimbursement
• Pertussis Market Appendix
• Pertussis Market DelveInsight Capabilities
• Pertussis Market Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.